Strata Critical Medical (BLDE) removes warrants expiring 05/07/2026 from Nasdaq

Rhea-AI Filing Summary

Strata Critical Medical, Inc. notified the Nasdaq Stock Market LLC of the removal of its warrants expiring 05/07/2026 from listing and/or registration under Section 12(b) of the Exchange Act. The notice cites compliance with Rule 17 CFR 240.12d2-2 and indicates the exchange and issuer followed the voluntary withdrawal procedures.

Key Figures

Commission File Number: 001-39046 Affected securities: warrants expiring 05/07/2026 Cited rule: 17 CFR 240.12d2-2 +1 more

4 metrics

Commission File Number 001-39046 Form 25 cover identification

Affected securities warrants expiring 05/07/2026 Class of securities being removed

Cited rule 17 CFR 240.12d2-2 Exchange compliance and voluntary withdrawal procedures

Issuer address ZIP 10017 Principal executive office address, New York, NY

Key Terms

Form 25, Section 12(b), 17 CFR 240.12d2-2, warrants expiring 05/07/2026

4 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) regulatory

"REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

warrants expiring 05/07/2026 financial

"Warrants expiring 05/07/2026 (Description of class of securities)"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39046

Issuer:	Strata Critical Medical, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	666 Third Avenue
	25th Floor
	New York	NEW YORK	10017
Telephone number:					212-967-1009

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Warrants expiring 05/07/2026

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-05-06	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Strata Critical Medical, Inc. (BLDE) file Form 25 with Nasdaq?

The filing notifies Nasdaq of the removal of the company’s warrants expiring 05/07/2026 from listing. It certifies that both the Exchange and the issuer complied with 17 CFR 240.12d2-2 procedures for voluntary withdrawal and strike from the exchange.

What securities are affected by the Form 25 filing for BLDE?

The filing specifically affects the company’s warrants expiring 05/07/2026. The notice identifies that class of securities as the subject of removal from Nasdaq listing and/or registration under Section 12(b) of the Exchange Act.

Does the Form 25 filing state who signed the notice for Nasdaq?

Yes. The notice is signed on behalf of Nasdaq Stock Market LLC by Jennifer Fainer, listed with the title CDO Analyst. It certifies Nasdaq had reasonable grounds to file the Form 25 under the cited rule.

Does the Form 25 filing specify timing or conditions for the removal?

The filing cites compliance with 17 CFR 240.12d2-2 and voluntary withdrawal procedures but does not state a separate effective removal date in the excerpt. It records procedural compliance rather than additional timing details.

Where is Strata Critical Medical, Inc. located according to the filing?

The filing lists the issuer’s principal executive office at 666 Third Avenue, 25th Floor, New York, NY 10017, and a telephone number 212-967-1009, as part of the issuer identification details in the Form 25.